Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD. et al
Case Number:
2:18-cv-06378
Court:
Nature of Suit:
Patent - Abbreviated New Drug Application(ANDA)
Judge:
Firms
Companies
Sectors & Industries:
-
September 17, 2020
Bristol Myers, Dr. Reddy's Settle Revlimid Patent Suits
Bristol-Myers Squibb unit Celgene will permit Dr. Reddy's Laboratories Ltd. to sell a generic version of its cancer drug Revlimid on a limited basis after March 2022 and then an unlimited amount in 2026, under a deal unveiled Thursday in Celgene's New Jersey federal suits alleging the Indian drugmaker infringed its patents.
-
April 13, 2018
Celgene Sues To Block Dr. Reddy's Revlimid Generic
Celgene Corp. on Thursday tried to block Dr. Reddy's Laboratories Ltd. from making and selling a generic version of its blockbuster chemotherapy drug Revlimid, accusing the Indian drugmaker in New Jersey federal court of infringing five patents.